mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CD59
Gene summary
Basic gene Info.Gene symbolCD59
Gene nameCD59 molecule, complement regulatory protein
CytomapUCSC genome browser: 11p13
Type of geneprotein-coding
Description1F5 antigen20 kDa homologous restriction factorCD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)CD59 glycoproteinLy-6-like proteinMEM43 antigenT cell-activating proteinhuman leukocyte antigen MIC11
Modification date20141221
dbXrefs MIM : 107271
HPRD : 00117
ProteinUniProt: P13987
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CD59
BioGPS: 966
PathwayNCI Pathway Interaction Database: CD59
Pathway Commons: CD59
ContextiHOP: CD59
ligand binding site mutation search in PubMed: CD59
UCL Cancer Institute: CD59
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

Ligand binding site mutations for CD59
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CD59
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CD59 from PDB

Differential gene expression and gene-gene network for CD59
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CD59 and the right PPI network was created from samples without mutations in the LBS of CD59. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CD59
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C2676767CD59 Deficiency3Biomarker, GeneticVariation

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CD59
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CD59 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CD59
Multiple alignments for P13987 in multiple species
LBSAA sequence# speciesSpecies
A41ADCKTAVNCSS1Homo sapiens
A41SSCKINTTCSP1Mus musculus
A41SSCKTNSTCSP1Rattus norvegicus
N43CKTAVNCSSDF1Homo sapiens
N43CKINTTCSPNL1Mus musculus
N43CKTNSTCSPNL1Rattus norvegicus
Q27SGHSLQCYNCP1Homo sapiens
Q27TAVSLKCYNCL1Mus musculus
Q27TGVSLRCYNCL1Rattus norvegicus
V42DCKTAVNCSSD1Homo sapiens
V42SCKINTTCSPN1Mus musculus
V42SCKTNSTCSPN1Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas